ClinicalTrials.Veeva

Menu

The Gut Microbiota of Bipolar and Depression

X

Xi'an Jiaotong University

Status

Unknown

Conditions

Major Depressive Disorder
Bipolar Disorder

Treatments

Genetic: Faecal genome

Study type

Observational

Funder types

Other

Identifiers

NCT03062332
TGMOBAD2017

Details and patient eligibility

About

Background: The gut microbiome is emerging as an important factor in regulating mental health yet it remains unclear what the target should be for psychiatric treatment. Investigators aim at elucidating the complement of the gut microbiome community for individuals with Major Depressive disorder (MDD) and Bipolar disorder (BD) relative to controls, and test for relationships with symptoms.

Methods: Investigators prospect to recruit subjects including patients and controls amount to 240. All subjects will be collected for blood and stool samples,assessed by clinical scales. Finally, analyzing the correlation among the metabolon in blood, microbiota in stool and clinical scales to obtain the possible interaction between diseases and gut microbiota.

Full description

Background: MDD (Major Depressive disorder) and BD (Bipolar disorder), whose specific pathogenesis is still unclear, are both a multi-factorial disease being caused by biological, psychological and social factors. Accumulating evidence suggests that gut microbiota play an important role in brain functions and in the pathogenesis of neuropsychiatric diseases, such as autism, anxiety, as well as depression. No study has thus far compared the human gut microbiota among BD, MDD and the healthy control (HC). The aim of this study is to compare the composition of fecal microbiota among BD, MDD and HC. Furthermore, investigators aim at identifying direct correlations between human fecal microbiota (as a proxy for gut microbiota) and symptoms.

Methods:

Investigators aim at recruiting human subjects in total 240, which including mania episode of bipolar disorder (40), depressive episode of bipolar disorder (40), mixed episode of bipolar disorder (40), first episode of major depressive disorder (40), recurrent episode of major depressive disorder (40), and healthy control (40). All patients, diagnosed according to the research criteria of the 10th revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-10), come from The First Affiliated Hospital of Xi'an Jiaotong University and controls are healthy volunteers. Collecting blood and stool samples, evaluating clinical scales including Montgomery-Asberg Depression Scale (MADRS), Young Mania Rating Scale (YMRS), Hamilton Depression Scale (HAMD), Hamilton Anxiety Scale (HAMA), Measurement And Treatment Research To Improve Cognition In Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB), Clinical Global Impression (CGI) are all finished in first day after threshold. Measure the metabolon in blood such as S-CFA, and gut microbiota. Using Statistical Program for Social Sciences (SPSS) to compare general and clinical data among groups and analyze the correlation between the microbiota and symptoms.

Enrollment

240 estimated patients

Sex

All

Ages

Under 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Conforms to the diagnosis of bipolar disorder or major depressive disorder.
  • Take antibiotics continuously less than 3 days in recent 3 months.
  • 17.5≦BMI≦30
  • Age≦65

Exclusion criteria

  • who is diagnosed with physical diseases and other mental diseases.
  • pregnant or lactational women
  • who is diagnosed with mental retardation.

Trial design

240 participants in 6 patient groups

Bipolar disorder,mania
Description:
The group includes subjects who are diagnosed to mania episode of bipolar disorder.
Treatment:
Genetic: Faecal genome
Bipolar disorder,depressive
Description:
The group includes subjects who are diagnosed to depression episode of bipolar disorder.
Treatment:
Genetic: Faecal genome
Bipolar disorder,mixed
Description:
The group includes subjects who are diagnosed to mixed episode of bipolar disorder.
Treatment:
Genetic: Faecal genome
First episode major depression
Description:
The group includes subjects who are diagnosed to first episode of major depression.
Treatment:
Genetic: Faecal genome
major depression,recurrent
Description:
The group includes subjects who are diagnosed to recurrent episode of major depression.
Treatment:
Genetic: Faecal genome
Healthy control
Description:
The group includes subjects who are Healthy control.
Treatment:
Genetic: Faecal genome

Trial contacts and locations

1

Loading...

Central trial contact

Xiancang Ma, professor; Wei Wang

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems